Targovax ASA: Second quarter and first half 2017 results
Oslo, Norway, 24 August 2017 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces its second quarter and first half 2017 results. A meeting for investors, analysts and press will take place in Oslo today at 10:00 CET and a conference call will take place at 14.00 CET (details below). HIGHLIGHTS FOR THE SECOND QUARTER AND FIRST HALF 2017 R&D · In February, Targovax announced encouraging top line two-year survival data from the phase I/II TG01 clinical trial in resected pancreatic cancer